Dividend Aristocrats with low P/E's and buying recommendations originally published at long-term-investments.blogspot.com. We all love a growing dividend and one of the most popular indices that cover the best dividend growth stocks is the S&P 500 Dividend Aristocrats index.

The index has currently 54 constituents. My goal in this article is to show you the currently cheapest stocks from the Dividend Aristocrats Index with current buy or better ratings.

I know, it's a little bit easy to trust others work but the high-quality dividend stocks are already discovered. The only thing we must do is to screen the current valuations and market opinions.

Only twelve stocks fulfilled both, a forward P/E below 15 combined with a buy or better rating by brokerage firms. Half of the results have a projected double-digit mid-term earnings growth forecast.

 Weekly Ex-Dividend Dates and Yields by Ex-Dividend Dates. Here is a current stock and Fund list of dividend stocks paying forthcoming dividends and having ex-dividend within the week September 09, 2012 - September 15, 2013. The average dividend-yield amounts to 4.45 percent.

Great Yields With Ex-Dividend Date Between September 09 - 15, 2013...

September 6, 2013 (www.investorideas.com newswire) Australian based investment house Jenepe Asset Management, in joint venture with London based IPO Capital Partners, has launched a fund targeting new listing opportunities.

The Certified Investment Management Analyst (CIMA) regulated fund, Jenepe IPO Capital Fund S.P., domiciled offshore in the Cayman Islands, will be managed by Nicholas Pereza-Mathews and will take positions in range of financial instruments focused on the Pre-IPO sector.

Mr Pereza-Mathews, who has over twenty years' experience in global markets and funds management working in London and Australasia, previously managed the Australian Natural Resources Fund, a top performing fund within its class achieving sound Alpha returns under his stewardship.

SAN DIEGO - September 5, 2013 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), announced today that Company Chairman and CEO, Jim Joyce has accepted an invitation to present at the Exosomes and Circulating Biomarkers 2013 Summit on September 12th. Mr. Joyce's presentation is entitled; "Extracorporeal Elimination of Circulating Exosomes as a Therapeutic Adjunct to Address Infectious Disease and Cancer." The presentation will highlight the clinical advancement of the Aethlon Hemopurifier® in treating hepatitis c virus (HCV) and discuss the opportunity to expand therapeutic indications to include cancer based on targeting the elimination of circulating tumor-secreted exosomes. The conference will be held at the Town and Country Resort Hotel in San Diego, California.